In connection with the closure of the German facility (which was part of the 2005 Agis acquisition), the Company incurred restructuring charges of approximately $15 million. Refer to Table II at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP disclosure information.
The Company's reported results are summarized in the attached Consolidated Statements of Income, Balance Sheets and Statements of Cash Flows. As part of management's strategic review of its portfolio of businesses, in March 2009, the Company committed to a plan to sell its Israel Consumer Products business. The results of this business are reflected in the consolidated financial statements as discontinued operations for all periods presented.
Perrigo Company
(from continuing operations, in thousands, except per share amounts)
(see the attached table II for reconciliation to GAAP numbers)
Fourth Quarter Fiscal Year
-------------- -----------
2009 2008 2009 2008
Net Sales $508,209 $474,282 $2,006,862 $1,729,921
Reported Income $32,280 $32,160 $141,098 $140,197
Adjusted Income $46,927 $42,151 $174,637 $154,485
Reported Diluted EPS $0.35 $0.34 $1.51 $1.47
Adjusted Diluted EPS $0.50 $0.44 $1.87 $1.62
Diluted Shares 93,290 95,076 93,629 95,210
Fourth Quarter Results
'/>"/>SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved
Related medicine news :
1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend